Drugs / Mupirocin
Mupirocin
also known as
Bactroban Nasal · Mupirocin calcium · Bactroban · Bactoderm · BACTROBAN Nasal ong · BRL 4910A · BRL 4910F · Calcium mupirocin · +12 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | BACTROBAN | — | 1999-04-22 | fda.gov ↗ |
| Approved | US (FDA) | BACTROBAN | — | 1987-12-31 | fda.gov ↗ |
Trials 43 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 35 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06046937 Comparator | Jun 2023 | bacterial infectious disease | Victoriano Luna Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01943136 Comparator | Aug 2013 → Jun 2015 | impetigo | Philippine Dermatological Society | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01594827 Background | Oct 2012 → Dec 2017 | cystic fibrosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01408056 Comparator | Feb 2011 → Jan 2014 | hemangioma | Children's Hospital of Philadelphia | Withdrawn | No outcome recorded |
| Phase 2 | NCT00626795 Comparator | Feb 2008 → Mar 2009 | impetigo | LEO Pharma | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05874219 Comparator | Apr → May 2023 | — | Future University in Egypt | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04155203 Comparator | Oct 2019 → Jun 2021 | skin disorder caused by infection | Padagis LLC | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT06633588 Comparator | May 2025 → Jun 2026 | staphylococcus aureus infection | Swiss Paraplegic Research, Nottwil | Completed | No outcome recorded |
| Phase 4 | NCT05586776 Comparator | Jan 2023 → Jan 2027 expected | — | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 4 | NCT02945722 Comparator | Feb 2018 → Oct 2024 | — | University Hospital of Saint-Etienne | Terminated | No outcome recorded |
| Phase 4 | NCT03140423 Comparator | May 2017 → Nov 2023 | staphylococcus aureus infection | Harvard Pilgrim Health Care | Completed | No outcome recorded |
| Phase 4 | NCT02029872 Comparator | Jan 2014 → Mar 2017 | methicillin-resistant staphylococcus aureus infectious disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT02218307 Comparator | Nov 2011 → Jun 2015 | chronic rhinosinusitis | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT01313182 Comparator | Mar 2011 → Sep 2012 | — | Solventum US LLC | Completed | No outcome recorded |
| Phase 4 | NCT01400308 Comparator | Feb 2010 → Dec 2011 | methicillin-resistant staphylococcus aureus infectious disease | B. Braun Medical SA | Terminated | No outcome recorded |
| Phase 4 | NCT00751374 Comparator | Sep 2008 → Oct 2014 | mycobacterial infectious disease | Kwong Wah Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00400595 Comparator | Feb 2006 → Jun 2009 | end stage renal failure | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT00179959 Comparator | Sep 2005 → Mar 2011 | atopic eczema | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT00108160 Comparator | Apr 2005 → Aug 2012 | staphylococcal infection | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 4 | NCT00801879 Comparator | Sep 2003 → Apr 2006 | HIV infectious disease, staphylococcus aureus infection | Columbia University | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT04047914 Comparator | Nov 2019 → Jan 2021 | chronic kidney disease | University of Nove de Julho | Completed | No outcome recorded |
| — | NCT03173053 Comparator | Feb 2018 → Oct 2021 | movement disorder, staphylococcus aureus infection | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT02560155 Comparator | Nov 2015 → Oct 2017 | musculoskeletal system disorder | Lindenhofgruppe AG | Completed | No outcome recorded |
| — | NCT02223520 Comparator | Nov 2014 → Oct 2019 | staphylococcus aureus infection | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT01814371 Comparator | Apr 2013 → Feb 2017 | abscess, furunculosis, methicillin-resistant staphylococcus aureus infectious disease | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT01820455 Comparator | Jan 2012 → Jan 2014 | — | University of Tennessee | Completed | No outcome recorded |
| — | NCT01269541 Comparator | Mar 2011 → May 2015 | — | Region Skane | Completed | No outcome recorded |
| — | NCT01209234 Comparator | Jan 2011 → Jan 2019 | methicillin-resistant staphylococcus aureus infectious disease | University of California, Irvine | Completed | No outcome recorded |
| — | NCT01918813 Background | Nov 2009 → Oct 2011 | hepatobiliary disorder, inflammatory bowel disease, pancreas disorder | Chikara Tashiro | Completed | No outcome recorded |
| — | NCT00980980 Comparator | Sep 2009 → Sep 2011 | methicillin-resistant staphylococcus aureus infectious disease | Harvard Pilgrim Health Care | Completed | No outcome recorded |
| — | NCT00731783 Comparator | Jul 2008 → Jan 2010 | abscess, furunculosis, methicillin-resistant staphylococcus aureus infectious disease | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00713674 Comparator | Mar 2008 → Feb 2009 | methicillin-resistant staphylococcus aureus infectious disease | Mercy Research | Withdrawn | No outcome recorded |
| — | NCT00513799 Comparator | Mar 2007 → Jun 2009 | abscess, furunculosis, staphylococcus aureus infection | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT01049438 Background | Aug 2006 → Sep 2009 | methicillin-resistant staphylococcus aureus infectious disease | Natividad Medical Center | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2003-11-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Mupirocin Ointment tevapharm.com ↗ |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 80 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mupirocin | “Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS...” NCT01232231 ↗77“Validated decolonization regimen consisting of intranasal 2% mupirocin ointment applied twice daily as well as chlorhexidine wash used daily to the body.” NCT05505214 ↗ “Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen.” NCT02063867 ↗ “The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole” NCT03303677 ↗ “Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash.” NCT00966446 ↗ “Provider choice of topical antibiotics includes Mupirocin 0.4mg/ml” NCT03935828 ↗ “nasal mupirocin for 5 days twice per month for 6 months” PMID 30763195 ↗ Feb 2019 “application of mupirocin ointment over the skin staples” NCT03081962 ↗ “mupirocin ointment into both nares BID for 2 weeks.” NCT01229553 ↗ “Mupirocin 2% nasal ointment to the anterior nares” NCT06397781 ↗ “use of mupirocin nasal ointment 3 times a day” NCT02945722 ↗ “Mupirocin, BACTROBAN® Nasal ong, 3g, GSK” NCT03962907 ↗ “Nasal mupirocin to apply twice daily.” NCT02182115 ↗ “Mupirocin” NCT02099240 ↗ |
| Known as | Bactoderm | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Bactroban | “Those colonized were randomized in a double-blind fashion to nasal mupirocin (Bactroban) twice daily and hexachlorophene (pHisoHex) soaps daily for 7 days compared to placeboes...” PMID 26018036 ↗ May 20151“Bactroban® (mupirocin) 2% cream” NCT00626795 ↗ |
| Known as | Bactroban Nasal | “For this clinical trial, all subjects will be given: nasal mupirocin (Bactroban Nasal, twice daily), topical 3% hexachlorophene body wash (Phisohex, daily), and an oral...” NCT01049438 ↗2“Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.” NCT00560599 ↗ “BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.” NCT04218799 ↗ |
| Known as | BACTROBAN Nasal ong | “Mupirocin, BACTROBAN® Nasal ong, 3g, GSK” NCT03962907 ↗ |
| Known as | BRL 4910A | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | BRL 4910F | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Calcium mupirocin | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Calcium mupirocin dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Calcium pseudomonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Centany | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Mupirocin calcium | “BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.” NCT04218799 ↗ |
| Known as | Mupirocin calcium anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Mupirocin calcium dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Mupirocin calcium hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Mupirocina | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Mupirocine | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | NSC-759182 | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Pseudomonic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Trans-pseudomonic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Known as | Turixin | ChEMBL registry synonym — accepted as the source's own label CHEMBL719 ↗ |
| Action | Inhibit | “This medicine works by killing bacteria or preventing their growth.” NCT06712433 ↗ |
| Modality | Small molecule | — CHEMBL719 ↗ |
| Route | Topical | “Drug or placebo will be applied topically to nares and/or wounds twice daily” NCT00108160 ↗ |